Proteon Therapeutics' lead product, PRT-201, is an investigational recombinant human elastase being developed to prolong patency and reduce failure of hemodialysis vascular access in patients with chronic kidney disease. Preclinical data suggest elastase can reduce neointimal hyperplasia and dilate segments of arteries and veins, which may improve blood flow and vessel patency. PRT-201 has received FDA fast track and orphan drug designations and an orphan medicinal product designation from the European Commission for hemodialysis vascular access indications. The company plans to initiate a Phase 3 study later this year to evaluate PRT-201 in patients undergoing surgical placement of an arteriovenous fistula (AVF). Proteon is headquartered in Waltham, Mass. The company concurrently raised financing to support its late-stage development program. Proteon Therapeutics is a privately held biopharmaceutical company based in Waltham, MA developing novel, first-in-class pharmaceuticals to address medical needs in renal and vascular diseases. Its lead candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls. Proteon is investigating whether elastase can be used to dilate arteries and veins and reduce neointimal hyperplasia where those effects would provide clinical benefit. The company is initially evaluating PRT-201 to improve outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis. PRT-201 has received FDA fast track and orphan drug designations for hemodialysis vascular access indications. Proteon recently completed a $15.2M financing, and lists a number of institutional and angel investors among its backers.

Total raised

$60M

Funding rounds

2

Latest round

Series D

Latest activity

May 2014